Let's focus on what we can do!

By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

  • Home
  • >
  • Latest Headlines
  • >
  • Dosing Begins in Phase 2a Trial of Oral Treatment to Aid Cognition — Parkinson’s News Today

Dosing Begins in Phase 2a Trial of Oral Treatment to Aid Cognition — Parkinson’s News Today

Tuesday, 13 September, 2022

Dosing Begins in Phase 2a Trial of Oral Treatment to Aid Cognition — Parkinson’s News Today

Patient dosing has begun in a Phase 2a clinical trial testing oral CST-2032 in combination with CST-107 as a potential way to ease the symptoms of mild cognitive impairment and mild dementia due to Parkinson’s or Alzheimer’s disease, the company developing these therapies, CuraSen Therapeutics, announced.

The trial (NCT05104463) follows positive findings in a Phase 1 multiple-dose study of CST-2032/CST-107 in healthy volunteers and patients with mild cognitive impairment, the company stated in a press release. CuraSen plans to present these findings at a future medical conference.

Enrollment of about 40 eligible patients, ages 50 to 80, in the placebo-controlled Phase 2a study is underway at various U.S. sites and in New Zealand, CuraSen stated. According to the study’s NCT document, eligible Parkinson’s patients are those with rapid eye movement (REM) sleep behavior disorder, which is linked to more severe symptoms and faster disease progression, but no hallucinations.

Read more at: https://parkinsonsnewstoday.com/news/trial-dosing-cst-2032-parkinsons-mild-cognition-treatment/

Categories :
  • Latest Headlines
  • Parkinson's
Socials :

Recent posts